Review Article
Apathy in Alzheimer’s Disease: Any Effective Treatment?
Table 3
Characteristics and outcome of clinical trials using different classes of compounds on apathy in Alzheimer’s disease.
| Study | Study design | Sample size | Intervention | Time | Apathy as a primary or secondary objective | Apathy instrument assessment | Outcome |
| Scripnikov et al., 2007 [25] | Randomized, double-blind, placebo-controlled | 400 | Ginkgo biloba extract EGb 761 (240 mg/day) | 22 weeks | Secondary | Neuropsychiatric Inventory (NPI) | Significant reduction in NPI apathy scores with Ginkgo biloba |
| Siddique et al., 2009 [26] | Retrospective analysis | 421 | Citalopram (5–30 mg/day) | 12 weeks | Primary | NPI | Use of citalopram was associated with reduced irritability and apathy without sedation |
|
|